Evidence map›Paper›PMID 42305631›Full record

ArticleiScience2026

Cellular immunology data enable clinical severity prediction via supervised machine learning.

Yonghyun Nam, Michelle L McKeague, Matei Ionita, Matthew E Lee, Mark Painter, Sokratis Apostolidis, Jaesik Kim, Jakob Woerner, Sang-Hyuk Jung, Patryk Orzechowski and 4 more

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yonghyun NamDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Michelle L McKeagueInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Matei IonitaInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Matthew E LeeDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Mark PainterInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sokratis ApostolidisInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jaesik KimDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jakob WoernerDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sang-Hyuk JungDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Patryk OrzechowskiDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Joost WagenaarDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Allison R GreenplateInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
E John WherryInstitute for Immunology & Immune Health (I3H), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Dokyoon KimDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dimensional flow cytometry provides rich immunological data for examining immune responses and their relationships with disease pathology, but its complexity, heterogeneity, high-dimensionality, and modest sample sizes limit translation into clinical applications. We describe a translational immune health framework that applies supervised learning algorithms to integrate high-dimensional cellular immunology data with clinical outcomes. Using COVID-19 as a clinical scenario, we applied this framework to deep immune profiles from patients to classify disease severity and predict future severity changes from baseline profiles. We built predictive models with five supervised algorithms and interpreted associations between immune features and severity outcomes with SHapley Additive exPlanations. This approach identified immune features contributing to severity predictions and provided interpretable links between cellular immune profiles and clinical outcomes. Our findings support machine learning as a practical strategy for analyzing complex immunological data and advancing predictive modeling in translational immune health.

Indexed as

artificial intelligencehealth informaticshealth sciencesmachine learningpredictive medicine

Identifiers

PMID42305631
PMCPMC13267612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.